By Fineline Cube 
Roche Holding AG (SWX: ROP; OTCMKTS: RHHBY) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Susvimo (ranibizumab injection) 100 mg/mL for the treatment of neovascular age-related macular degeneration (nAMD). Susvimo is designed for continuous release into the vitreous using the Contivue implant, with a final European Commission decision expected in the near future.
Regulatory Milestone
| Item | Detail |
|---|---|
| Company | Roche Holding AG (SWX: ROP; OTCMKTS: RHHBY) |
| Product | Susvimo (ranibizumab injection) 100 mg/mL with Contivue implant |
| Indication | Neovascular age-related macular degeneration (nAMD) |
| Regulatory Body | EMA/CHMP (European Union) |
| Recommendation Type | Positive opinion recommending marketing authorization |
| Delivery System | Port Delivery Platform (Contivue implant) |
| CE Mark Status | Contivue implant granted CE mark in 2025 |
| Next Steps | European Commission final decision expected shortly |
Product Profile & Innovation
- Therapeutic Class: Anti-vascular endothelial growth factor (anti-VEGF) agent
- Active Ingredient: Ranibizumab (same molecule as Lucentis)
- Delivery Innovation: Continuous drug delivery via surgically implanted Contivue reservoir
- Dosing Frequency: Two refills per year versus monthly intravitreal injections
- Patient Benefit: Reduces clinic visit frequency while maintaining equivalent visual outcomes
- Technical Specification: Contivue implant specifically engineered for use with Susvimo formulation
Clinical Evidence – Pivotal Trial Data
| Endpoint | Result (Susvimo) | Comparator (Monthly IVT Ranibizumab) | Equivalence |
|---|---|---|---|
| Visual Acuity Outcomes | Equivalent maintenance | Standard of care | Non-inferior |
| Supplemental Treatment Need | 5% required additional anti-VEGF | N/A | 95% treatment independence |
| Long-term Vision Maintenance | Up to 7 years (Portal study) | Limited long-term data | Sustained efficacy |
| Safety Profile | Generally well tolerated over long term | Known ranibizumab safety profile | Consistent with class |
The recommendation is based on data from three clinical studies:
- Archway: Pivotal Phase III study demonstrating equivalence to monthly ranibizumab
- LADDER: Phase II supportive study
- Portal: Open-label long-term extension study showing vision maintenance up to seven years
Market Impact & Strategic Outlook
- nAMD Market Size: Affects approximately 1.5 million patients in EU5 countries with annual treatment costs exceeding €3 billion
- Treatment Burden: Current standard requires monthly or bimonthly intravitreal injections, creating significant patient and healthcare system burden
- Competitive Positioning: First continuous-delivery anti-VEGF therapy approved in Europe, offering differentiated dosing schedule
- Revenue Potential: Analysts project peak annual sales of €450-600 million if approved, capturing 15-20% of the nAMD market
- Healthcare Economics: Potential to reduce clinic visits by 80%, generating significant healthcare system savings through reduced administration costs
- Strategic Significance: Strengthens Roche’s ophthalmology portfolio alongside existing Lucentis franchise and complements Genentech’s US commercialization efforts
Forward‑Looking Statements
This brief contains forward-looking statements regarding regulatory timelines, clinical outcomes, and commercial expectations for Susvimo. Actual results may differ due to risks including final approval conditions, market adoption, competitive dynamics, reimbursement decisions, and surgical implant adoption rates among retinal specialists.-Fineline Info & Tech